MSD supports national skin cancer campaign

MSD supports national skin cancer campaign

Lucerne, 2 May 2018 - This year's National Skin Cancer Day will take place on 15 May. As part of the National Skin Cancer Campaign, it aims to raise public awareness of the importance of early detection of skin cancer. In addition, many dermatologists in Switzerland offer free initial examinations of conspicuous moles on certain days in May. MSD is committed to educating and preventing skin cancer worldwide and to providing the best possible treatment for affected patients. On May 15, MSD supports an event for patients and their families at the University Hospital Zurich.

According to figures from the Cancer League, around 2700 people in Switzerland contract melanoma (black skin cancer) every year.1 This is about 7% of all cancers.1 Melanoma is the fifth most common type of cancer.1 Black skin cancer can also occur in younger people: 24% of people suffering from melanoma are younger than 50 at the time of diagnosis.1 If a melanoma is detected and removed early, there is usually a good chance of recovery.2 In advanced melanoma, the prognosis is unfavorable for affected patients. In Switzerland, around 320 people die of the disease every year. 3

Free initial examination of conspicuous moles as part of the campaign
Experts agree: "Early detection of skin cancer is central and can save lives".4 For this reason, the Swiss Society for Dermatology and Venerology (SGDV) once again calls on its members to participate in the national skin cancer campaign.4 Participating dermatologists agree to examine conspicuous moles of interested people free of charge on certain days in May. The SGDV publishes on its Website.

MSD is committed to the fight against cancer
With more than 650 clinical studies across a wide variety of cancers and treatment settings, MSD operates the most comprehensive research program in the world for immuno-oncology.5 MSD has made an important contribution to improving the treatment options for melanoma patients in recent years. In Switzerland, MSD works with various partners to advance innovative solutions in cancer treatment. One example is the expert think tank Immuno-oncology, the results of which have been published.6 As part of the National Skin Cancer Campaign, MSD is supporting an event for patients and their families at the University Hospital Zurich on May 15, 2018, at which experts from the Dermatological Clinic and the Clinic for Plastic Surgery and Hand Surgery will provide information on skin cancer prevention (especially sun protection) and the latest treatments for skin cancer.
More information about the event:
More information about melanoma and how you can prevent a disease can be found here: Infocenter.


Dr. Angelika März, Director Policy & Communications
MSD Merck Sharp & Dohme AG
Tel. +41 58 618 35 18 / Mobile 079 378 02 47

About MSD
MSD is a leading global biopharmaceutical company which has been engaged in life science research for more than a century, developing drugs and vaccines for the most challenging diseases worldwide. MSD is a registered trademark of Merck & Co., Inc., Kenilworth, New Jersey, USA. With our prescription drugs, vaccines, biological therapies, and veterinary products, we offer innovative health solutions in over 140 countries. With wide-ranging programs and partnerships, we are also committed to achieving improved access to healthcare. Today MSD is still at the forefront of research for the prevention and treatment of diseases which threaten people and society around the world, including cancer, cardiovascular diseases, new animal diseases, Alzheimer’s, and infectious diseases, including HIV and Ebola. For more information visit and follow us on Twitter.

MSD Human Medicine Switzerland
Switzerland is a key location for the company, which has 700 employees working there in national and international functions. The Human Medicine division in Switzerland is responsible for the distribution of prescription drugs and biopharmaceuticals in the areas of oncology, diabetes, cardiovascular diseases, infectious diseases (including fungal infections, antibiotic resistance, HIV/Aids, and hepatitis C), immunology, women’s health as well as vaccines for children, young people, and adults.

MSD is active in clinical research in Switzerland, where the company provides medicines for clinical trials worldwide. Additionally, MSD is committed to raising health literacy and promoting the healthcare economy on a local level. The company is also active in Lucerne, where the MSD headquarters are located. In 2018 the company received certification as a “Top Employer” in Switzerland for the sixth year in succession, as well as the “Top Employer Europe” award for the third time.

More information is available at:
Follow us on Twitter: @MSD_Switzerland

CORP-1241900-0015, created April 2018

© 2018 MSD Merck Sharp & Dohme AG, Werftestrasse 4, 6005 Lucerne. All rights reserved.